CompletedNCT00167154
Risperidone added to antidepressants for suicidal thoughts in major depression
About this title
Risperidone and Suicidality in Major Depressive Disorder
Read the official source — NCT00167154Medication studyAges 19–60United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 19 years to 60 years. Other eligibility criteria applied.
- Listed locations
- BirminghamSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- University of Alabama at Birmingham
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 19 Years to 60 Years
- Official registry ID
- NCT00167154
- Official title
Show the full official title
Efficacy of Risperidone in the Management of Suicidality in Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Alabama at Birmingham, a university.
Did this study involve medication?
Yes. The study involved medication, including Risperidone and placebo comparator.
Who was this study for?
This study was for people with depression. Listed age limits: 19 years to 60 years. Other eligibility criteria applied.
